INDIA’S HOSPITAL BUSINESS : Who Profits When Healthcare Becomes Unaffordable?

 

BIZ MASALA  |  FORENSIC BUSINESS INVESTIGATION

 

INDIA’S HOSPITAL BUSINESS

Who Profits When Healthcare Becomes Unaffordable?

A forensic look at hospital margins, medicine mark-ups, household costs and the limits of price regulation

 

EDITORIAL HERO IMAGE • Conceptual illustration; not a photograph of a specific hospital or family.

By Murthy ASR  |  11 October 2026

 

The story in one minute

India’s hospital sector is expanding rapidly, and listed hospital groups are reporting strong operating performance. Yet households still pay a large share of the country’s healthcare bill directly. The tension is real; the causal story is more complicated. A hospital’s margin is not proof of overcharging, and high out-of-pocket expenditure includes spending across the health system—not just corporate hospitals. The investigation therefore asks a sharper question: where are prices opaque, where do patients lack meaningful choice, and which rules can make bills more predictable without choking investment or quality?

24.1%	43.4%	₹2,700 → ₹27,000
FY2026 operating profit margin reported for ICRA’s sample of 11 listed hospital companies.	Out-of-pocket spending share of total health expenditure in India in 2022–23.	A reported cancer-medicine price example cited amid recent Supreme Court scrutiny; not a claim about all hospitals or medicines.

These three figures describe different things. They must not be treated as proof that hospital margins directly cause household spending.

1. The paradox: profitable providers, exposed households

ICRA’s July 2026 update says its sample of 11 listed hospital companies recorded 18% year-on-year revenue growth in FY2026, average occupancy of 63.5%, and a 9.2% increase in average revenue per occupied bed per day. The sample’s operating profit margin was 24.1%. ICRA expects revenue growth of 13–15% in FY2027 and operating margins of 22–24% in FY2027 and FY2028. These are sample-based industry estimates, not the performance of every hospital.

Chart 1. ICRA’s listed-hospital sample. FY2027–FY2028 are forecasts; the midpoint is plotted for visual comparison.

A margin is not a moral verdict. Hospitals need to pay clinicians and nurses, maintain expensive equipment, finance new beds, comply with safety standards and absorb periods of low occupancy. But sustained growth and strong margins make transparency more important: patients should be able to understand what they are paying for, and policymakers should be able to distinguish efficient investment from avoidable or excessive charges.

2. What the national health accounts actually say

The Union Health Ministry’s National Health Accounts estimates for 2022–23 put out-of-pocket expenditure (OOPE) at 43.4% of total health expenditure, down from 64.2% in 2013–14. The share had been 39.4% in 2021–22, so the latest year is a rise from the pandemic-period low. Government health expenditure rose from 28.6% to 43.7% of total health expenditure between 2013–14 and 2022–23.

Chart 2. Out-of-pocket expenditure share. The 2021–22 dip occurred during unusually high government spending during the COVID period.

Chart 3. Government health expenditure share of total health expenditure.

Interpretation matters. OOPE includes direct household spending across providers and services, including medicines and outpatient care; it is not a private-hospital bill index. The national accounts show that financial protection has improved over the decade, but also that households still finance a substantial share of healthcare directly.

3. The medicine-mark-up flashpoint

Recent reporting says the Supreme Court questioned steep mark-ups on cancer medicines, citing an example of a medicine reportedly supplied at ₹2,700 and sold at ₹27,000. The issue is especially sensitive when patients are seriously ill, treatment is urgent, and the hospital’s own pharmacy may be the easiest or only practical source during admission.

The example is a reported case—not a representative sample of hospital pharmacy pricing. It does not establish that every hospital or every medicine carries a tenfold mark-up. A defensible investigation must establish the exact product and pack size, procurement price, applicable price-control status, tax and distribution costs, the actual selling price, and whether the patient had a realistic alternative.

The Competition Commission of India has previously examined alleged unfair pricing by super-specialty hospitals and published policy material discussing compulsory purchase of consumables from in-house pharmacies. Those are regulatory concerns and past scrutiny, not a blanket finding that every provider behaves unlawfully.

4. Why the final bill can be hard to predict

Hospital bills bundle many services: room category, doctor visits, nursing, operating theatre, diagnostics, medicines, implants, consumables, intensive care and discharge-related charges. The same procedure may also vary by patient complexity, emergency status, length of stay, infection risk, technology used and the hospital’s capabilities. A fair comparison must adjust for these differences.

Bill component	Question the investigation should ask	Evidence required
Medicines	Was a lower-cost equivalent available and clinically appropriate?	Product, pack size, price-control status, procurement and billed price
Implants / consumables	Were brand and model choices explained before use where feasible?	Itemised bill, device details, procurement invoices where obtainable
Diagnostics	Were tests clinically indicated and repeated? What are comparable rates?	Doctor’s order, test names, dates and published tariffs
Room and nursing	Did room category change trigger linked rate changes?	Admission estimate, tariff schedule, final bill
Insurance settlement	What was disallowed, capped or paid by the family?	Policy wording, pre-authorisation, final settlement statement

5. The insurance illusion: a paid claim is not a fully paid bill

Insurance can protect families from large bills, but the existence of a policy does not guarantee that every line item will be reimbursed. Room-rent limits, exclusions, sub-limits, co-payments, non-payable items, package caps and disagreements over medical necessity can leave patients with a balance.

For this story, we should not use a single claims-paid percentage as a proxy for consumer protection. The more useful measures are the share of billed amount reimbursed, the median patient balance, claim repudiation and partial-settlement rates, time to settlement, and how these differ by policy and hospital type. These figures should be clearly dated and drawn from regulator or insurer disclosures.

6. The regulatory gap is partly a federalism problem

Health is primarily a state subject. The central Clinical Establishments Act has been adopted by a specified set of States and Union Territories; the Ministry’s current portal lists Telangana among them. The framework addresses registration and minimum standards, and the central rules provide for display of rates where applicable. But the existence of a framework is not the same as uniform, effective enforcement across every state and hospital.

A key policy distinction: standardising disclosure and itemised billing is not identical to imposing one national price for every treatment. Procedure costs differ for legitimate reasons. A workable approach could combine transparent tariffs, comparable package definitions, independent clinical audit, clear consent for non-emergency upgrades, grievance redressal and targeted regulation of products where market power or patient vulnerability is especially acute.

7. The investment case hospitals will make—and why it matters

Private hospital operators can reasonably argue that new capacity requires capital, that advanced care depends on expensive equipment and specialist staff, and that predictable returns attract investment into underserved markets. The listed-company data support the proposition that organised hospitals are expanding and operating profitably; they do not by themselves tell us whether prices are fair.

The public-interest test is not ‘profits are bad’. It is whether patients can compare prices before non-emergency treatment, whether the bill reflects care actually delivered, whether medically necessary treatment is accessible, whether outcomes are measured alongside cost, and whether public money paid through government schemes purchases value.

8. The Hyderabad / South India lens

A local case study can make this national story concrete, but only if comparisons are fair. We should compare a small set of common procedures across hospitals using the same clinical definition, room category, inclusions and exclusions. A quoted ‘starting price’ cannot be compared with an all-inclusive final bill. Publicly available tariffs and package rates should be labelled as such, and any patient bill must be anonymised and used with permission.

·       Choose 4–6 comparable procedures, such as cataract surgery, normal delivery, C-section, angioplasty, knee replacement and selected oncology regimens.

·       Record what each quote includes: surgeon, anaesthesia, room, implants, medicines, tests, follow-up and taxes.

·       Separate cash tariffs, insurer-negotiated packages and government scheme packages; they are different prices for different payment arrangements.

·       Do not rank hospitals by price alone. Add quality and safety indicators only where comparable, credible data exist.

We should not name a hospital as an offender based on a price difference alone. The right to respond, documentary support and clinical context are essential before making any allegation.

9. What the evidence supports—and what it does not

Supported by available evidence	Not established by these figures alone
Listed hospital groups have reported strong revenue growth and operating margins.	That every private hospital is overcharging or earning the same margins.
OOPE was 43.4% of total health expenditure in 2022–23.	That 43.4% of household healthcare spending went to corporate hospitals.
Recent scrutiny has highlighted a reported extreme cancer-medicine price example.	That the example is typical, verified across the market, or attributable to every hospital pharmacy.
India has a regulatory framework and state-level implementation responsibilities.	That laws are uniformly enforced or that a single national price cap is necessarily optimal.
A hospital bill can contain many components and insurance exclusions.	That every disputed test or item was unnecessary or improper.

10. Biz Masala verdict

The real scandal may not be that hospitals make profits. It may be that patients often cannot tell, before treatment, what they will pay, why they will pay it, or how much insurance will leave uncovered.

The evidence points to a transparency and accountability problem worth investigating—not a licence to condemn an entire sector. India needs hospitals that can invest, recruit and innovate. It also needs patients who are not forced to make high-stakes decisions without usable price information. The next step is a documented procedure-price comparison and a close reading of itemised bills, package terms and regulatory enforcement.

Publication checklist: evidence still to collect

·       Collect dated tariffs and package definitions for selected procedures from hospitals in Hyderabad and at least one comparison city.

·       Check the current status and exact scope of any proposed cancer-medicine trade-margin cap before publication.

·       Obtain audited annual reports for selected listed hospital groups; distinguish operating profit, EBITDA, net profit, capex and debt.

·       Verify any patient-bill example against original documents, anonymise personal details and request the hospital’s response.

·       Compare insurer-approved package rates with cash tariffs only when the procedure and inclusions are identical.

·       Check the latest Telangana rules, notifications, complaint channels and enforcement records.

Sources and research trail

1.       ICRA, 30 July 2026 — Strong demand and 6–8% rise in ARPOB to support healthy revenue growth of 13–15% in FY2027
https://www.icra.in/Research/ViewResearchReport/strong-demand-and-6-8-rise-in-arpob-to-support-healthy-revenue-growth-of-13-15-in-fy2027/7044

2.       Press Information Bureau / Ministry of Health, 27 May 2026 — National Health Accounts Estimates for India 2022–23
https://www.pib.gov.in/PressReleasePage.aspx?PRID=2265816&lang=1&reg=3

3.       Indian Express, October 2026 — Public-health groups seek cap on hospital charges and medicine margins; reports Supreme Court scrutiny
https://indianexpress.com/article/cities/pune/jsa-working-group-on-access-to-medicines-and-treatment-demand-ceiling-on-hospital-charges-regulation-on-medicine-price-10907977/

4.       Financial Express, October 2026 — Cancer drug price caps and potential hospital-sector effects
https://www.financialexpress.com/market/cancer-drug-price-caps-why-jefferies-picks-fortis-apollo-manipal-despite-sc-scrutiny-4357411/

5.       Competition Commission of India, 5 September 2018 — Investigation scope in alleged unfair pricing by super-specialty hospitals
https://www.cci.gov.in/antitrust/press-release/details/185/0

6.       Competition Commission of India — Policy note on competition in healthcare
https://www.cci.gov.in/public/images/advocacy_event/en/policy-note-01652182274.pdf

7.       Ministry of Health and Family Welfare — Clinical Establishments Act portal
https://www.clinicalestablishments.mohfw.gov.in/

8.       PIB, 18 December 2017 — Charges on health services and state-level regulatory responsibility
https://www.pib.gov.in/PressReleasePage.aspx?PRID=1513028&lang=2&reg=48

9.       Ministry of Health and Family Welfare — Patient Charter (draft; rights language should be checked against applicable law and state rules)
https://www.mohfw.gov.in/sites/default/files/PatientCharterforcomments.pdf

Methodology and caveats

This is a desk-research first cut dated 11 October 2026. National health-account figures refer to total health expenditure and must not be read as private-hospital-only data. ICRA figures describe its sample of 11 listed hospital companies; forecasts are not actual results. The cancer-medicine example is attributed to current media reporting and requires primary-document verification before stronger claims are made. Historical CCI scrutiny and policy notes do not establish present misconduct by any named provider. No hospital-specific allegation is made in this draft. Figures and legal status should be rechecked immediately before publication.

Editorial standard: distinguish official data, company disclosures, estimates, reported allegations and our own analysis. Give named entities a fair opportunity to respond before publishing any adverse claim.